Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction

Avery SchwartzDepartment of Anatomy and Cell Biology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Shany BlumDepartment of Anatomy and Cell Biology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Rabea AslehDepartment of Anatomy and Cell Biology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Mordechai PollakDepartment of Anatomy and Cell Biology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Shiri Kalet-LitmanDepartment of Anatomy and Cell Biology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Andrew P LevyDepartment of Anatomy and Cell Biology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, IsraelCorrespondence[email protected]

Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date